Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: Results of a prospective, randomized, multicenter study
Antoni Rimola, Joan M. Salmerón, Gerardo Clemente, Luis Rodrigo, Antoni Obrador, M. Luisa Miranda, Carlos Guarner, Ramon Planas, Ricard Solá, Victor Vargas, Fernando Casafont, Francesc Marco, Miquel Navasa, Rafael Bañares, Vicente Arroyo, Joan Rodés – 1 March 1995 – Cefotaxime (CTX) is considered one of the first‐choice antibiotics in the therapy of spontaneous bacterial peritonitis (SBP) in cirrhosis. Because CTX is largely metabolized in the liver, this drug may also be effective in SBP by administering lower doses than those habitually used.